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Abstract
Background: Epstein-Barr Virus (EBV) is found in 10% of all gastric adenocarcinomas but its role in tumor
development and maintenance remains unclear. The objective of this study was to examine EBV-mediated
dysregulation of cellular factors implicated in gastric carcinogenesis.
Methods: Gene expression patterns were examined in EBV-negative and EBV-positive AGS gastric epithelial cells
using a low density microarray, reverse transcription PCR, histochemical stains, and methylation-specific DNA
sequencing. Expression of PTGS2 (COX2) was measured in AGS cells and in primary gastric adenocarcinoma tissues.
Results: In array studies, nearly half of the 96 human genes tested, representing 15 different cancer-related signal
transduction pathways, were dysregulated after EBV infection. Reverse transcription PCR confirmed significant
impact on factors having diverse functions such as cell cycle regulation (IGFBP3, CDKN2A, CCND1, HSP70, ID2, ID4),
DNA repair (BRCA1, TFF1), cell adhesion (ICAM1), inflammation (COX2), and angiogenesis (HIF1A). Demethylation
using 5-aza-2’-deoxycytidine reversed the EBV-mediated dysregulation for all 11 genes listed here. For some
promoter sequences, CpG island methylation and demethylation occurred in an EBV-specific pattern as shown by
bisulfite DNA sequencing. Immunohistochemistry was less sensitive than was western blot for detecting
downregulation of COX2 upon EBV infection. Virus-related dysregulation of COX2 levels in vitro was not
recapitulated in vivo among naturally infected gastric cancer tissues.
Conclusions: EBV alters human gene expression in ways that could contribute to the unique pathobiology of
virus-associated cancer. Furthermore, the frequency and reversability of methylation-related transcriptional
alterations suggest that demethylating agents have therapeutic potential for managing EBV-related carcinoma.
Background
Gastric cancer is the fourth most common type of can-
cer and the second leading cause of cancer death world-
wide [1]. A variety of genetic alterations as well as
infectious and other environmental agents appear to be
factors in gastric carcinogenesis. Epstein-Barr virus
(EBV), a double-stranded DNA gammaherpesvirus, is
found within the malignant cells in 10% of gastric ade-
nocarcinomas, and infection seems to precede malignant
transformation [2]. Basic and clinical observations sug-
gest that EBV-associated gastric cancers have a different
pathobiology from EBV-negative gastric cancers [3-8].
Rational design of virus-directed therapy requires a bet-
ter understanding of the pathogenic role of EBV in gas-
tric carcinogenesis.
Prior studies have shown loss of three critical tumor
suppressor gene products, CDH1 (E-cadherin), p73,
and CDKN2A (p16), in EBV-infected gastric cancers
[9-18]. Virus-associated methylation of these genes,
along with evidence of global DNA methylation in
EBV-positive cancers, suggests that EBV-related gastric
cancers are a subset of CpG island methylator pheno-
type (CIMP) cancers [4,11,19-26]. A potential mediator
is DNA methyltransferase 1 (DNMT1) that is upregu-
lated in naturally infected gastric cancers and could
help establish methylation patterns propagated to
daughter cells upon cell division [21,27-29]. Ongoing
studies are aimed at understanding the role of EBV
and Helicobacter pylori infection in causing
* Correspondence: margaret_gulley@med.unc.edu
4Department of Pathology and Laboratory Medicine and the Lineberger
Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
27599-7525, USA
Full list of author information is available at the end of the article
Ryan et al. Infectious Agents and Cancer 2010, 5:27
http://www.infectagentscancer.com/content/5/1/27
© 2010 Ryan et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
inflammation and associated global hypermethylation
during gastric cancer development [22].
In cell line models, DNMT1 overexpression is
mediated by EBV LMP1 and LMP2 [21,28-31]. EBV
seems to employ epigenetic mechanisms to control the
host transcriptome and also to control expression of
its own virally encoded genes [11,12,14,15,19,21,
24,29,32,33]. Upon initial infection of a cell, the
unmethylated viral genome can undergo viral replication
with new virion production, while a subset of infected
cells acquire a highly methylated viral genome that
squelches expression of foreign proteins and mediates
long-term viral persistence by way of latent infection
[23,34]. Infected tumors tend to have highly methylated
EBV DNA, and methylation-related silencing of viral
genes helps explain how infected tumors evade immune
destruction.
While methylation of gene promoters is typically asso-
ciated with transcriptional downregulation via selective
binding of repressor proteins, the first protein ever
shown to bind and activate a methylated promoter was
EBV BZLF1, the key factor controlling the switch from
latent to replicative forms of viral infection [35]. It
appears that the virus has cleverly evolved a means of
overcoming promoter methylation to its advantage
[34,35]. Antiviral strategies are being explored for their
antineoplastic potential. Interestingly, the most com-
monly used antiviral agents, acyclovir and ganciclovir,
are effective at shutting down viral replication but they
do not eliminate expression of latent and early lytic viral
genes such as LMP1, LMP2 and BZLF1.
The clinical implications of EBV-related methylation
of the gastric cancer genome are immense. First, emer-
ging evidence shows the potential for improved diagno-
sis of gastric cancer by testing gastric washes for
cancer-specific methylation patterns, perhaps in concert
with tests for EBV to identify the virus-infected subset
of cancers [36-40]. Differing patterns of promoter
methylation in virus-positive compared to virus-negative
cells [11,21,24] emphasize the need to characterize
methylation patterns in a manner that that maximizes
assay sensitivity for cancer detection. Both infection and
altered DNA methylation appear to be early events in
carcinogenesis [2,41], potentially facilitating detection of
precancerous lesions in stomach juice.
A second clinical implication is the potential for
improved treatment of gastric cancer using drugs that
reverse the effect of promoter hypermethylation [42,43].
In particular, demethylating agents that inhibit DNA
methyltransferase and reverse tumor suppressor gene
silencing or oncogene activation are potential antineo-
plastic strategies [43]. Consideration must be given to
possible differences in the effect of demethylating agents
in virus-positive versus virus-negative tumors [43-45].
We and others have shown that naturally infected gas-
tric cancers have lower CDKN2A (p16) expression
[14,15]. In a clinical trial of fluorouracil (5FU) for gastric
cancer, CDKN2A promoter methylation status was an
independent predictor of survival [46]. The rationale for
using demethylating agents like 5-aza-2’-deoxycytidine
in clinical trials rests on scientific evidence that
demethylating therapy modifies the tumorigenic proper-
ties of cancer cells.
Several investigators have successfully infected epithe-
lial cell lines with EBV in vitro [47,48]. In the current
study, EBV-positive and EBV-negative AGS gastric can-
cer cells were examined for differences in gene expres-
sion patterns using low-density microarray analysis and
reverse transcription polymerase chain reaction (rtPCR).
AGS is a cell line that was originally grown from gastric
adenocarcinoma tissue and now is widely used as a
model of gastric cancer. The role of DNA methylation
in mediating selected effects was examined by bisulfite
DNA sequencing and by testing the ability of a
demethylating agent to reverse the effect of EBV on
gene silencing. Results revealed extensive gene dysregu-
lation upon EBV infection in AGS cells with evidence
that promoter methylation is responsible, at least in
part. Reversal of virus-associated transcriptional effects
suggests that demethylating agents should be explored
for their potential to control growth of EBV-related
malignancies.
Methods
Gastric Cancer Cell Lines
The AGS gastric cancer cell line (ATCC CRL-1739) was
cultured in Dulbecco’s Modified Eagle’s Medium con-
taining 10% fetal bovine serum (heat-inactivated for 20
minutes at 65°C) and 1% penicillin-streptomycin (10,000
units penicillin, 10,000 μg/ml streptomycin, Gibco,
Carlsbad, CA). The cells were infected with a recombi-
nant EBV strain (a gift from Dr. Henri J. Delecluse)
[33,49,50] that was engineered to express green fluores-
cence protein (GFP) and hygromycin B resistance by
cloning these genes into the prototypic B95.8 strain of
EBV where the second copy of oriLyt normally resides.
Before infection, AGS cells were transfected with 1 μg
of an expression vector encoding CD21 (the EBV recep-
tor) and a puromycin resistance gene by using Fugene 6
(Roche, Indianapolis, IN) as previously described [51].
At 48 hours post-transfection, cells containing CD21
were positively selected for using 0.5 μg/mL of puromy-
cin-HCl (Roche). Viral stocks of recombinant EBV were
generated in kidney 293 cells, a human embryonic
epithelial cell line, by inducing lytic replication using 20
ng/mL phorbol 12-tetradecanoate 13-acetate and 3 mM
butyrate. Supernatants were harvested 3 days after
induction, filtered (0.8 μM), and frozen at -80°C until
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use. Puromycin-resistant AGS cells were plated at 50%
of full density in 60-mm tissue culture dishes and co-
incubated with 1 mL of stock virions. Four days later,
the EBV-infected AGS cells (now called AGS-B95-
HygB) were positively selected with 100 μg/mL hygro-
mycin B (Roche).
DNA fingerprinting confirmed that AGS cells used in
this study matched the genotype of AGS cells in the
American Type Culture Collection. Fingerprinting was
done using the PowerPlex 1.2 STR kit (Promega) fol-
lowed by electrophoresis on an ABI 310 capillary gel
electrophoresis instrument (Applied Biosystems).
Gene Expression by Histochemical Stains
Paraffin blocks were prepared from AGS and AGS-B95-
HygB cell lines, and paraffin blocks of primary gastric
adenocarcinoma were retrieved from clinical archives.
The residual clinical specimens represent all available
EBV positive gastric cancers (n = 9) and a random
selection of EBV-negative gastric cancers (n = 9). Histo-
chemical stains were applied to paraffin sections to con-
firm infection and to evaluate gene expression. To
prepare blocks, cultured cells were first rinsed in Dul-
becco’s phosphate buffered saline (Gibco, Invitrogen),
harvested with 0.25% trypsin (Gibco, Invitrogen),
enmeshed in a clot using Dade Ci-Trol Coagulation
Control (Citrated)-Level 1 (Dade Behring, Marburg,
Germany) and Thrombin 200 (Pacific Hemostasis, Mid-
dletown, VA), fixed in 10% buffered formalin, embedded
in paraffin, and sectioned onto coated slides.
EBER in situ hybridization was performed using fluor-
escein-labeled EBER probe and oligo(d)T control probe
on a Benchmark in situ hybridization system (Ventana
Medical Systems, Tucson, AZ). Immunohistochemical
stains for EBV LMP1 and LMP2 proteins were per-
formed as previously described [52] using citrate antigen
retrieval and the CS1-4 cocktail of mouse monoclonal
antibodies against LMP1 (1:100, Dako, Capinteria, CA)
and the E411 rat monoclonal antibody against LMP2 (1
mg/ml, Asencion, Munich, Germany). Paraffin sections
of EBV-related Hodgkin lymphoma and post-transplant
lymphoproliferative disorder served as positive controls.
Immunohistochemical analysis of the EBV replicative
proteins BMRF1 and BZLF1 was performed using anti-
BMRF1 clone G3-E31 (1:200 dilution, Research Diagnos-
tics, Inc., Flanders, NJ) and anti-BZLF1 clone BZ.1 (1:25
dilution, Dako, Carpinteria, CA), while human PTGS2
(colloquially named cyclooxygenase-2, COX2) was
assayed using anti-COX2 monoclonal antibody (1:200
dilution, Cayman Chemical). Sections were incubated
with primary antibody for 30 minutes at 37°C for the
EBV targets, or at 4°C overnight for COX2, using the
blocking and detection protocols in the Super-Sensitive
Non Biotin HRP Detection Kit (Biogenex). Bound
antibody was detected using diaminobenzidine chromo-
gen (Biogenex) and cells were counterstained with
hematoxylin (Dako). Paraffin sections of oral hairy leu-
koplakia served as a positive control for lytic EBV, while
reactive tonsil and nasopharyngeal carcinoma tissues
served as controls for COX2 stains. Results were inter-
preted by microscopic scoring of malignant cells in ≥10
fields at 400x magnification yielding an average propor-
tion score (0 = none, 1 = <1%, 2 = 1-10%, 3 = 10-33%,
4 = 33-66%, 5 = >66% of cells) and intensity score (0 =
none, 1 = weak, 2 = intermediate, 3 = strong staining).
Total scores were compared in EBV positive versus
negative tumors using a Mann-Whitney unpaired t test.
Detection of the EBV genome
A battery of quantitative real-time PCR (Q-PCR) assays
targeting six disparate regions of the EBV genome was
used to demonstrate that viral infection of AGS cells
was successful. Amplified products were detected using
the ABI Prism 7500 Real-Time PCR instrument with
Sequence Detection System software (Applied Biosys-
tems) as previously described using primers targeting
the BamH1W, EBNA1, LMP1, LMP2, and BZLF1
regions of the EBV genome [52] or EBER1 DNA [53].
To check for amplicon contamination, every run con-
tained at least two “no template” controls in which
nuclease-free H2O was substituted for template.
Low-Density cDNA Microarray Analysis
RNA was isolated from AGS and AGS-B95-HygB cells
using the RNeasy RNA Mini Kit (Qiagen) after first
using the QiaShredder™ spin column (Qiagen) to lyse
the cells. After confirming RNA integrity using an Agi-
lent Bioanalyzer, expression microarray analysis was per-
formed by SABiosciences Corporation (Frederick, MD)
using their GEArray Q Series Human Signal Transduc-
tion in Cancer Gene Array. This low-density microarray
consists of 96 probes that test activation of 15 signal
transduction pathways involved in oncogenesis. (Target
transcripts are listed in Results.) Biotin-labeled cDNA
prepared from 10 μg of each RNA sample using the
AmpoLabeling-LPR method (SABiosciences) was hybri-
dized to the array, and chemiluminescent detection was
performed using a CCD camera. Integrated raw intensity
values for each spot were generated by GEArray Analy-
sis Suite software (SABiosciences), and further analysis
and normalization was performed using Microsoft Excel.
The lowest spot intensity value on each array was con-
sidered to be background and was subtracted from each
raw intensity value for each probe, and then spot inten-
sities were normalized to that of the housekeeping gene,
glyceraldehydephosphate dehydrogenase (GAPDH). A
pairwise comparison of gene expression levels was made
between the EBV-positive cells (AGS-B95-HygB) and
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parental EBV-negative AGS cells. If the ratio was ≥2 or
≤0.5, the gene was considered to be upregulated or
downregulated in infected cells.
SYBR Green Semiquantitative rtPCR
To confirm selected microarray gene expression results,
rtPCR was performed using Real-Time RT2 gene-speci-
fic PCR primers (SABiosciences). The ReactionReady™
First Strand cDNA Synthesis Kit (SABiosciences) was
used to convert 3 μg of RNA to cDNA, and the cDNA
was diluted 1:10 before PCR analysis. The following 38
cDNAs were targeted: GAPDH, A2M, ABCB1, BCL2L1,
BIRC1, BIRC2, BIRC3, EN1, GADD45, HIF1A, ID2,
IGFBP3, BRCA1, TMEPAI, IRF1, BCL2, BMP4,
CDKN2A (p16), FN1, HK1, ICAM1, IL2, CCND1,
MDM2, COX2 (PTGS2), TFRC, WISP1, TRAF1, CDK2,
VCAM1, CDKN2C (p18), CDKN1A (p21), DUSP1,
HSP70, NFKB1, TNFSF10, TRIM25, and FOSL1. Reac-
tions were performed in a total volume of 25 μL
containing 1X TaqMan® Universal Mix (ABI), RT2
gene-specific primer set mix (10 μM each primer,
SABiosciences), 2.5 μL 5X SYBR green solution (Mole-
cular Probes, Eugene, OR), and 5 μL of cDNA template.
Thermocycling conditions were: 50°C for 2 minutes, 95°
C for 10 minutes, and 40 cycles of 95°C for 15 seconds
and 60°C for 1 minute on an ABI 7500 instrument with
Sequence Detection System software (Applied Biosys-
tems). The same threshold was used for each gene and
plate evaluated by the “Relative Quantification Plate”
protocol. Each PCR reaction was run in triplicate for
each sample on two separate 96-well plates, and results
were averaged to determine relative differences in each
gene’s expression level in the EBV-positive versus EBV-
negative cell line.
Minor Groove Binding Probe Semiquantitative rtPCR
To evaluate expression of five selected genes that were
not on the microarray described above, semi-quantita-
tive rtPCR assays were performed (Assays-on Demand,
Applied Biosystems) using minor groove binding probes
targeting helicase-like transcription factor (HLTF), trefoil
factor-1 (TFF1), basic-leucine zipper ATF-like transcrip-
tion factor (BATF), inhibitor of DNA binding protein-4
(ID4), and nucleostemin (NU). These five were selected
because they are reportedly dysregulated in a substantial
proportion of gastric adenocarcinomas or EBV-related
cancers [32,54-59]. GAPDH served as an endogenous
control for relative quantification purposes. RNA was
converted to cDNA using the High Capacity cDNA
Archive Kit (Applied Biosystems), and the cDNA was
diluted 1:10 with nuclease-free water. Each 50 μL PCR
reaction contained: 1X TaqMan® Universal Master Mix,
1X Target Gene Expression assay or GAPDH Endogen-
ous Control mix, and 10 μL cDNA. To check for
amplicon contamination, every expression assay on
every plate contained at least two “no template” controls
in which nuclease-free water was substituted for tem-
plate. Thermocycling conditions and data analysis were
as described above for the SYBR Green rtPCR.
Demethylation Treatment and Sequencing of Bisulfite-
modified DNA
To study the effect of demethylation, the AGS and
AGS-B95-HygB gastric cancer cell lines were grown to
75% confluency and then for three consecutive days 1
μM of fresh 5-aza-2’-deoxycytidine (5aza; Sigma) was
added daily. On the fourth day, RNA and DNA were
harvested from treated and untreated cultures. RNA was
evaluated for gene expression levels, and DNA was
examined for methylation after sodium bisulfite treat-
ment (EZ DNA Methylation Kit, Zymo Research,
Orange, CA) to convert unmethylated cytosines to ura-
cil, while keeping methylated cytosines unchanged [60].
The positive control was CpGenome Universal Methy-
lated DNA (Chemicon) subjected to the same bisulfite
conversion, and control primers targeting the C8orf4
cellular gene promoter confirmed successful bisulfite
conversion of each DNA sample [61]. CpG islands were
identified using CpG Plot for each of five human genes–
ICAM1 (RefSeq# NM_00201), CDKN2A (p16) (RefSeq#
NM_000077.3), ID4 (RefSeq# NM_001546), COX2
(RefSeq# NM_000963), and TFF1 (RefSeq# 003225.2)–
for which promoter sequences (3000 basepairs upstream
of the transcription start site through exon 1) were
downloaded from GenBank. The following parameters
for CpG island identification were used: minimum
length of 200 bp, minimum average percentage of C+G
of 50%, and minimum average ratio of observed to
expected C+G of 0.6 [62]. To identify CpG dense
regions for COX2 and TFF1, the minimum length para-
meter was reduced to 50 bp [61]. Primer sequences are
shown in Table 1. Each 50 μl PCR reaction contained:
1X PCR Buffer, 2 mM MgCl2, 1 unit Platinum Taq
DNA Polymerase (Invitrogen, Carlsbad CA), 0.2 mM
dNTPs (ABI), and 30 pmol of each primer. Thermocy-
cling conditions were: 94°C for 2 minutes, 40 cycles of
94°C for 30 seconds, 55°C for 30 seconds, and 72°C for
1 minute, 72°C for 10 minutes. To monitor amplicon
contamination, every run contained a “no template”
control in which nuclease-free water was substituted for
template
Sequencing was performed on amplicons of bisulfite-
treated templates to identify the methylated and
unmethylated CpGs with or without 5aza treatment.
First, each PCR product was cloned into pGEM-T vec-
tor using the pGEM-T Easy Vector System II (Promega)
and transformed in JM109 high efficiency competent
cells. White colonies containing inserts were selected
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and cultured overnight, and plasmid DNA was extracted
using the QiaPrep Spin Miniprep Kit (Qiagen). Sequen-
cing was done on an ABI 3100 Genetic Analyzer using
the ABI PRISM™ BigDye™ Version 1.1 Terminator Cycle
Ready Reaction Kit with AmpliTaq DNA Polymerase
and an M13R3 primer. Results were downloaded into
Sequencher software (Gene Codes, Ann Arbor, MI) to
obtain the reverse compliment of each sequence, and
both forward and reverse sequences were aligned and
analyzed to distinguish unmethylated cytosines from
methylated cytosines.
Western Blot on the AGS cell line
Because of the potential for COX2 inhibitor therapy to
overcome COX2 effects, the RNA-based results for
COX2 were chosen for follow-up study at the protein-
level. Confluent AGS cells with or without EBV were
harvested with 0.25% trypsin, washed twice in phos-
phate-buffered saline, and pelleted by centrifugation.
Cells were resuspended in 500 ul NP-40 cell lysis buffer
(50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, pH 8.0),
incubated on ice for 30 minutes, and spun at 12,000
rpm for 15 minutes at 4°C. Aliquots of lysate (at 50,
100, 150 ug protein per well) were resolved using SDS-
PAGE on a tris-glycine 4-20% gradient gel (Invitrogen)
and transferred onto a nitrocellulose membrane. COX2
was detected with a 1:5,000 dilution of the monoclonal
antibody followed a 1:10,000 dilution of secondary anti-
body conjugated with alkaline phosphatase (Amersham
Biosciences), and visualization with a Typhoon Phos-
phorImager (Molecular Dynamics). Band density mea-
sured semi-quantitatively and normalized to beta actin
(ACTB) was compared between infected and uninfected
AGS cells.
Results
EBV Infection of AGS Gastric Cancer Cells
Successful EBV infection of AGS gastric cancer cells was
confirmed using six Q-PCR assays targeting disparate
segments of the EBV genome. EBER in situ hybridiza-
tion showed no EBER expression in the parental
“EBV-negative” AGS cells, whereas greater than 90% of
AGS-B95-HygB cells were EBER-positive and had acti-
vated-appearing nuclear morphology (Figure 1). The
proliferation rate was increased as shown by confluence
of cultured AGS-B95-HygB cells three days prior to par-
ental AGS cells. The infection persisted for at least 4
months as shown by GFP and EBER histochemical
stains. EBV latent (LMP1 and LMP2A) and lytic (BZLF1
and BMRF1) proteins were not expressed in uninfected
AGS cells, whereas ~10% of infected cells expressed
LMP1, half the cells expressed LMP2A, and ~35%
expressed BMRF1 and BZLF1 proteins implying active
viral replication (Figure 1).
Cellular Gene Expression Differences in EBV-positive
versus EBV-negative AGS Cells
Expression levels of 96 cellular genes were analyzed in
AGS and AGS-B95-HygB cells using low density micro-
array analysis with chemiluminescent detection (Figure
2). After normalization to GAPDH, pairwise comparison
of gene expression levels between the EBV-positive and
EBV-negative AGS cells revealed that of the 96 genes on
the microarray, 43 were dysregulated at least two-fold
after EBV infection. Surprisingly, an EBV-associated
increase in expression was observed for only 6 genes
(IGFBP3, GADD45, IRF1, Grp78/HSPB1, GLUT1/
SLC2A1, TMEPAI), while decreased expression was
observed for the remaining 37 dysregulated genes
(ABCB1,BCL2L1, BIRC2,BMP2, CDKN2A, DUSP1,
HIF1A,ICAM1, ID2, NFKB1, COX2, TFRC, VCAM1,
WISP1, TRIM25, IL2, BMP4, MDM2, CCND1, CDK2,
BAX, p57, p19, CSN2, CXCL9, IL4, JUN, KLK3, LTA,
MMP7, PPARG, TNFRSF10B, WIG1, WNT2, PTCH2).
SYBR Green rtPCR was used to check the microarray
findings for 26 of the dysregulated genes and for 12
additional genes in which no significant change was
observed on the microarray. Greater than two-fold
alteration in mRNA level in infected versus uninfected
Table 1 Bisulfite Converted Gene-Specific PCR Primer
Sequences
ICAM1 Forward 5’-TGG GGG TTG TGG TTT TAG TT-3’
Reverse 5’-CTC CCT CCA CTA AAA AC-3’
Amplicon
size
412 bp
CDKN2A
(p16)
Forward 5’-AGA TGT TTT GTG GTT GTT GTG A-3’
Reverse 5’-CAA AAA TCT TCC ATT CTT CAA AC-3’
Amplicon
size
418 bp
ID4 Forward 5’-TTT TTT GGG TAT ATA TTA GTT TGG-
3’
Reverse 5’-TAT CCT AAT CAC TCC CTT C-3’
Amplicon
size
477 bp
COX2 Forward 5’-TAT GTG TTG TAT ATA GAG TAG A-3’
Reverse 5’-AAA AAA TAA TCC CCA CTC TC -3’
Amplicon
size
399 bp
TFF1 Forward 5’-TTA GGT TGG AGT GTA GTA GG-3’
Reverse 5’-CCT ACT CAT ATC TAA AAA ACC C-3’
Amplicon
size
489 bp
C8orf4
control
Forward 5’-GAA TTA AAA TAT AAG GAG AGT
TTT-3’
Reverse 5’-AAC ATT ACC CAA ACA TAA AAC AA-
3’
Amplicon
size
328 bp
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cells was found for 16/26 genes (Table 2). The genes
most strongly affected were IGFBP3 that was upregu-
lated by 42-fold, and COX2, BMP4, and ICAM1 that
were downregulated by 35-, 32-, and 22-fold, respec-
tively. The remaining ten microarray-based alterations
were not confirmed by rtPCR, suggesting that EBV-
related dysregulation of these factors was lower than
two-fold. In one instance, there was a major discre-
pancy: Expression levels of BCL2L1 by microarray
analysis showed a two-fold decrease in infected cells
while rtPCR repeatedly showed a five-fold increase in
BCL2L1 mRNA levels in infected cells. Less dramatic
discrepancies were found when an additional 12 genes
were analyzed by rtPCR, with significant (>2-fold)
changes found in the expression of 5/12 genes for which
no alteration was observed on the microarray (Table 2).
When rtPCR was used to evaluate expression of each
of 5 selected genes (HLTF, BATF, ID4, TFF1, and NU)
Figure 1 AGS-B95-HygB cells express latent and lytic viral genes. A) Immunohistochemical stain for GFP suggests hygromycin B-treated
AGS cells were uniformly infected by the engineered B95.8 EBV genome. B) EBER in situ hybridization indicates latent infection in >90% of cells.
Nuclear EBER staining spares the nucleoli, and enlarged nucleoli are a marker of cellular activation. Latent viral proteins LMP1 (C) and LMP2 (D)
were expressed focally. Lytic viral proteins, BMRF1 (E) and BZLF1 (F), were expressed in a significant fraction of AGS-B95-HygB cells. (GFP and
BMRF1 stains, 800x; LMP1, LMP2, EBER and BZLF1 stains, 1200x)
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that were not on the microarray, all except for HLTF
was downregulated by more than five-fold in the EBV-
positive AGS cells (Table 2). BATF and TFF1 were most
significantly affected (38-fold and 21-fold decrease,
respectively).
Demethylation Alters Cellular Gene Expression in AGS
and AGS-B95-HygB cells
If gene promoter methylation contributed to EBV-
related alterations in gene expression, then demethyla-
tion could reverse the effect and perhaps even restore
baseline gene expression. To explore this possibility,
AGS and AGS-B95-HygB cells were cultured in the pre-
sence or absence of 5aza. On the fourth day, RNA was
isolated from treated and untreated cells, and rtPCR was
performed to measure mRNA levels.
Figure 3 displays the effect of EBV infection on levels
of 11 selected genes that encode proteins having a wide
range of functions including cell cycle regulation and
proliferation (CDKN2A/p16, CCND1, IGFBP3, HSP70,
ID2, ID4), DNA repair (BRCA1, TFF1), cell adhesion
(ICAM1), immune response (COX2), and angiogenesis
Figure 2 Gene expression patterns are altered by EBV infection of AGS cells. Biotin-labeled cDNA probes arrayed in quadruplicate on a
nylon membrane hybridize to RNA isolated from AGS and AGS-B95-HygB cells. Chemiluminescent signals indicate dysregulation of selected
genes among the 96 on the array as compared with control genes in the last two rows.
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(HIF1A) [21,23,27,29-37]. Treatment with 5aza had vary-
ing effects depending on the gene and infection status.
Five of the 11 genes (ID2, IGFBP3, CDKN2A, ID4, and
CCND1) responded to 5aza treatment with higher
mRNA levels, consistent with promoter methylation in
the parental AGS cells. In contrast, decreased expression
of 4 factors (BRCA1, HIF1A, ICAM1, and COX2) was
observed in response to 5aza treatment, possibly because
transcriptional repressors of these genes were demethy-
lated. For the remaining factors (HSP70 and TFF1), 5aza
had no significant effect in AGS cells, suggesting that
these genes are not regulated by methylation in the
absence of EBV.
In AGS-B95-HygB cells, reduced mRNA levels were
observed for 10 genes upon EBV infection, but treat-
ment with 5aza was not sufficient to fully restore
expression of any of the genes except for ID2 and
CCND1 where complete reversal of the downregulation
was seen (Figure 3). For the remaining 8 genes
there was partial restoration of expression upon
demethylation.
IGFBP3 upregulation in uninfected cells treated with
5aza suggests that an inhibitor of IGFBP3 is normally
methylated in AGS cells, and that 5aza demethylates the
inhibitor to induce IGFBP3. EBV infection also strongly
induces IGFBP3, but subsequent 5aza treatment does
not further induce gene expression rather it partly
reverses the effect of EBV on IGFBP3 induction. Overall,
these results suggest that methylation is a mechanism by
which EBV influences cellular gene expression, and that
demethylation can partially or completely restore base-
line expression levels.
Bisulfite DNA Sequencing Reveals EBV-specific
Methylation
Comparisons of methylation patterns were made
between 5aza treated and untreated AGS and AGS-B95-
HygB cells to explore whether EBV-specific methylation
was a plausible cause for dysregulation of five selected
genes and to show how patterns of methylation were
affected by 5aza. The targeted promoter region for each
gene contains multiple CpG dinucleotides: The
CDKN2A region has 34 sites, ID4 has 53 sites, COX2
has 25 sites, ICAM1 has 35 sites, and TFF1 has 14 CpG
sites.
Bisulfite sequencing showed CDKN2A (p16) was
methylated at 30/34 CpG sites (88%) in both AGS and
AGS-B95-HygB cells. After 5aza treatment, only 22-31%
of sites remained methylated in AGS cells, whereas 70%
of sites remained methylated in AGS-B95-HygB cells
(Figure 4A) in concert with restored p16 expression
from 24-fold to 6-fold below baseline (Figure 3). The
findings imply a dramatic effect of EBV infection on p16
levels, and a more dramatic 5aza-related increase of p16
in infected cells compared to uninfected ones. The dra-
matic change in expression despite a minimal change in
promoter methylation (88 to 70%) after 5aza treatment
of infected cells suggests the likelihood of mechanisms
other than promoter demethylation.
EBV infection did not increase methylation of ID4
since its promoter was already largely methylated before
infection occurred. Bisulfite sequence analysis of ID4
showed 96-100% methylation in both AGS and AGS-
B95-HygB cell lines (Figure 4B). Upon treatment with
5aza, methylation of 92-96% of CpG sites was seen in
both infected and uninfected cells, and this seemingly
small change in methylation status was accompanied by
induction of ID4 mRNA. It is feasible that there is a
non-methylation mechanism of ID4 regulation by EBV.
Interestingly, bisulfite sequencing analysis of COX2
showed that individual gene promoters were either com-
pletely unmethylated or else largely methylated in AGS
Table 2 Genes Dysregulated in EBV-positive AGS Cells
Gene Name Gene
Symbol
Fold
Change*
Downregulated Genes
basic leucine-zipper transcription factor,
ATF-like
BATF -38
cyclooxygenase-2 COX2 -35
bone morphogenic protein-4 BMP4 -32
intercellular adhesion molecule-1 ICAM1 -22
trefoil factor-1 TFF1 -21
inhibitor of DNA binding-2 ID2 -14
heat shock protein-70 HSP70 -10
cyclin-dependent kinase-2 CDK2 -9
cyclin-D1 CCND1 -9
hypoxia inducible factor-1A HIF1A -9
breast cancer-1 BRCA1 -7
nucleostemin NU -7
cyclin-dependent kinase inhibitor-2A CDKN2A/p16 -6
inhibitor of DNA binding-4 ID4 -6
engrailed-1 EN1 -5
ATP-binding cassette, sub-family B,
member 1
ABCB1 -3
MDM2 p53 binding protein MDM2 -3
Upregulated Genes
insulin-like growth factor binding protein-3 IGFBP3 +40
tumor necrosis factor receptor-associated
factor-1
TRAF1 +20
transmembrane prostate androgen-induced
protein
TMEPAI +10
tumor necrosis factor, superfamily
member-10
TNFSF10 +8
B cell lymphoma-2-like-1 BCL2L1 +7
baculoviral IAP repeat containing-3 BIRC3 +5
hexokinase-1 HK1 +5
FOS-like antigen-1 FOSL1 +3
*Listed are genes dysregulated by >2-fold using rtPCR
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and in infected AGS cells, with somewhat different CpG
hypermethylation patterns in infected compared to
uninfected clones (Figure 4C) accompanied by a marked
loss of COX2 expression (Figure 3). In the presence of
5aza, there was dramatic demethylation of the COX2
promoter in AGS cells with only 0 to 6% methylation.
In contrast, the COX2 promoter was either completely
methylated or only half methylated in various clones of
AGS-B95-HygB cells treated with 5aza, suggesting hemi-
methylation of alleles in a given cell or else cell-to-cell
heterogeneity with respect to COX2 methylation pat-
terns. On average, COX2 mRNA levels were similar in
infected versus uninfected cells after treatment with
5aza. (Figure 3). Further work is needed to determine,
in any given cell, how methylation status relates to
COX2 levels and viral status (e.g. latent or lytic infec-
tion). In any case, EBV substantially influences COX2
expression and also impacts 5aza effects on its
promoter.
ICAM1 had distinct methylation patterns in infected
versus uninfected AGS cells, suggesting that EBV influ-
ences expression of this gene via promoter methylation
(Figure 4D). Upon EBV infection, methylation of CpG
sites increased slightly from 89 to 94%, particularly at
sites #33 and 34, and this subtle change was associated
with a pronounced decrease in ICAM1 expression.
Treatment of both cell lines with 5aza yielded demethy-
lation of 6-20% of the CpG sites to achieve similar
Figure 3 EBV-related alteration of gene expression is often reversed by treatment with a demethylating agent. Bar graphs show
substantial dysregulation of 11 genes upon EBV infection, as tested by rtPCR, with zero representing baseline expression levels in parental AGS
cells. Treatment of uninfected cells with 5-aza-2’-deoxycytidine (5aza) reveals induction of ID2, ID4, CCND1, CDKN2A (p16) and IGFBP3, suggesting
pre-existing promoter methylation. Treatment of infected cells reveals that demethylation can overcome the effect of EBV infection on virus-
induced gene dysregulation, at least in part. The most marked drug effect was seen in ID2, CCND1 and COX2 where demethylation virtually
completely reversed the impact of viral infection.
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mRNA levels, which in the infected AGS cells repre-
sented a restoration of levels from 24-fold to 9-fold
below baseline.
The most dramatic viral-driven changes in promoter
methylation were seen in the TFF1 gene. The TFF1 pro-
moter was 50-64% methylated in AGS cells but 100%
methylated in the infected counterpart. In particular,
CpG sites #10-14 were methylated upon infection and
tended to remain methylated even after attempting to
demethylate them with 5aza (Figure 4E.) In EBV-positive
AGS cells, 5aza demethylated 14-36% of sites and sub-
stantially induced TFF1 expression from 30-fold to 12-
fold below baseline, whereas in EBV-negative cells
demethylation of 43-93% of sites had no effect on TFF1
expression. Overall, these findings provide evidence that
EBV alters cellular gene expression by direct or indirect
effects on promoter methylation, and demethylation can
partially overcome viral effects on gene expression.
Protein-based analysis confirms virus-associated
downregulation of COX2 in AGS cells but not in primary
gastric adenocarcinoma tissues
COX2 was chosen for analysis at the protein level
because of the translational potential for COX2 inhibitor
therapy to overcome its effects. Lysates of EBV negative
and EBV positive AGS cells were compared in western
blot analysis. After normalization, COX2 expression in
EBV-positive cells was 1.5 to 2.1 fold (average 1.9) lower
than in EBV negative cells, confirming the RNA-based
finding that COX2 levels are downregulated by EBV in
this gastric epithelial cell line. In histologic sections of
gastric adenocarcinoma, COX2 protein was localized to
the cytoplasm and surface membrane of malignant cells,
without significant staining of the nucleus. COX2 was
also expressed in a fraction of tumor-infiltrating lym-
phoid cells. In EBER-negative cancers (n = 9), malignant
cells had a mean proportion score of 3.3 and intensity
Figure 4 Promoter methylation is a plausible mechanism of EBV-mediated dysregulation of multiple genes. Bisulfite sequencing reveals
methylation patterns of five genes: A) CDKN2A (p16), B) ID4, C) COX2, D) ICAM1, and E) TFF1. Methylation patterns are shown for several clones of
each gene with or without EBV infection, and with or without 5-aza-2’-deoxycytidine (aza) treatment. In each clone, methylated sites are dark red
ovals whereas unmethylated sites are light blue ovals.
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score of 1.8, while EBV-positive cancers had a mean
proportion score of 3.5 and intensity of 2.4. Total scores
were not significantly different in relation to EBV status
(p = 0.07). Likewise, immunohistochemistry of AGS
cells did not exhibit a visible difference in COX2 expres-
sion in relation to EBV status (Figure 5), suggesting that
immunohistochemistry is less sensitive to changes in
protein level than is western blot.
Discussion
Our research suggests that DNA methylation is a
mechanism by which EBV alters cellular gene expres-
sion, and that virus-related methylation can be reversed,
at least in part, by a demethylating agent. Since gross
chromosomal abnormalities and microsatellite instability
are less frequently detected in EBV-associated gastric
cancer compared to EBV negative cancer, it is feasible
that DNA hypermethylation is a primary driver of virus-
related oncogenesis that can be capitalized upon in
designing therapeutic interventions [19,21].
It is difficult to analyze the natural effect of EBV
infection on gastric cells because laboratory models only
partially reflect the effects of EBV infection occurring in
vivo. For example, LMP1 expression is unusual in natu-
rally infected tumors whereas LMP1 was expressed in
10% of our infected AGS cells [2,63-71]. Low level lytic
replication is sometimes reported in naturally infected
gastric cancers while it is regularly reported in infected
gastric cancer cell lines including our AGS-B95-HygB
line [2,65-69,72]. Other limitations of this study are that
only one gastric cell line was examined and the
demethylating agent was applied for only three days.
Nevertheless, our pilot work showing effects of EBV
infection on cellular gene expression and promoter
methylation in AGS cells encourages further investiga-
tion of the prospect of using demethylating agents to
overcome virus-associated effects in vivo.
The observed viral replication in infected AGS cells
might be aided by EBV-mediated downregulation of
CCND1 and ID2 to achieve S-phase-like cellular condi-
tions that are favorable for viral replication [73]. One of
the EBV lytic proteins, BMRF1, was previously shown to
upregulate gastrin [74], and high levels of gastrin are
implicated in gastric tumor development [75]. Lytic
Figure 5 Western blot but not immunohistochemistry reveals downregulation of COX2 expression in association with EBV infection.
Monclonal antibody was used to semiquantitatively measure COX2 protein. A. Western blot of AGS cell lysates (loaded onto the gel at 50, 100,
or 150 ug per lane) showed that EBV positive AGS cells had lower expression of COX2 than did EBV negative cells. However, COX2
immunohistochemistry revealed no discernible difference between EBV negative (B) and EBV positive (C) AGS cell lines. Likewise, COX2
immunohistochemistry of primary gastric adenocarcinoma tissue revealed no visible difference in COX2 expression between EBV negative cancer
(D) versus EBV positive cancer (E).
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infection is reportedly induced by 5aza [45], suggesting
possible pathways of 5aza effect beyond demethylating
promoters. Khan et al showed TFF1 expression is
directly induced by gastrin [76], so 5aza-mediated rever-
sal of TFF1 loss might be explained in part by indirect
effects on viral replication and gastrin induction in addi-
tion to the observed demethylation of the TFF1 promo-
ter. TFF1, which encodes trefoil factor 1, is suggested to
be a tumor suppressor gene that is lost or methylated in
many gastric cancers [77]. Interestingly, prior studies
suggest that EBV-related hypermethylation is stimulated
by pre-existing promoter methylation [19,21,29], and
our data on TFF1 as well as ICAM1 promoters would
support this characteristic.
Prior studies showed loss of ID4 expression in about
30% of gastric cancer as well as a means to upregulate
ID4 using 5aza in gastric cell lines [32]. Our work shed
light on the impact of EBV infection by demonstrating
strong downregulation of ID2 and ID4 upon infection.
ID2 and ID4 are members of a family of “inhibitor of
differentiation” transcriptional regulators. In breast can-
cer, methylation-related silencing of ID4 is a poor prog-
nostic indicator, and demethylation is proposed as a
means of overcoming ID4 repression [78]. In our own
demethylation studies, we showed that ID2 and ID4
silencing could be reversed by 5aza in AGS cells.
COX2 encodes an enzyme critical for prostaglandin
production that mediates inflammation in the gastroin-
testinal tract. COX2 may contribute to carcinogenesis by
promoting apoptosis resistance, angiogenesis, invasive-
ness, and by affecting host immunity [79-88]. COX2
gene silencing by hypermethylation in gastric carcinoma
cells was previously reported [18,89,90]. Our data show
that EBV infection causes a 50-fold decrease in COX2
mRNA levels in infected compared to uninfected AGS
cells. At the protein level, western blot confirmed down-
regulation of COX2 in EBV-infected AGS cells although
the magnitude of change was less dramatic at about
two-fold. Nearly complete restoration of baseline mRNA
expression upon demethylation suggests a potential
pharmacologic means of reversing the viral effect. The
clinical implications of such a finding are intriguing
given the reported beneficial effects of COX2 inhibition
on incidence, recurrence and outcome of gastrointest-
inal malignancy [88,91]. Follow-up studies are warranted
to explore if COX2 testing of gastric cancer tissue iden-
tifies patients most likely to benefit from COX2 inhibi-
tion. RNA-based assays may be more informative than
immunohistochemistry given our evidence that immu-
nostains were uniquely incapable of quantifying changes
in COX2 levels in response to EBV infection of AGS
cells. Another group found that COX2 immunostain
results were prognostic even though they were not
EBV-associated in a series of patients treated for gastric
cancer [92].
Heritable polymorphisms in COX2 and in IGFBP3
have been reported to affect the risk of developing gas-
tric cancer [91,93,94]. IGFBP3 is thought to reduce gas-
tric cancer metastasis by sequestering IGFs to prevent
them from triggering receptor tyrosine kinases [95].
Methylation of the IGFBP3 promoter is found in 67% of
gastric cancers, and its silencing is predicted to increase
tumor aggressiveness [96]. Our data on upregulation of
IGFBP3 in response to 5aza treatment confirms a pre-
vious study done on uninfected AGS cells [43]. Interest-
ingly, Lee et al reported that high IGFBP3 expression is
a positive predictive marker for response to the antineo-
plastic drugs paclitaxel and etoposide, suggesting that
EBV-infected cancers overexpressing IGFBP3 might be
particularly susceptible to these chemotherapeutic
agents [97]. If confirmed, these insights could impact
tumor classification schemes and assist in managing
patients with gastric cancer.
Conclusions
EBV infection had a profound effect on expression of
IGFBP3. Unlike IGFBP3 transcripts which were upre-
gulated, most of the tested gene were downregulated
by EBV infection. Methylation may be a common
mechanism for diverse effects of viral infection. To
the extent that viral infection is associated with
methylation in vivo, demethylating agents could pro-
vide a unified therapeutic approach to overcoming
viral effects.
Demethylating agents are already used clinically for
managing certain neoplasms [98], and their efficacy in
EBV-related gastric cancer should be considered. Our
pilot data shows frequent and substantial restoration of
multiple transcripts in 5aza-treated, infected cells. Pilot
sequencing data identify selective effects of virus infec-
tion and 5aza treatment on promoter methylation, pro-
viding an impetus for further work to characterize
viral-mediated effects and to understand how treat-
ments might be devised to overcome viral effects in
tumor cells.
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